版本:
中国

BRIEF-Novartis receives FDA approval for first-of-its-kind kisqali femara co-pack for initial treatment of hr+/her2- advanced or metastatic breast cancer

May 8 Novartis Ag

* Novartis receives FDA approval for first-of-its-kind Kisqali® Femara® co-pack for initial treatment of hr+/her2- advanced or Metastatic breast cancer Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐